SCAP and familial hypercholesterolemia: These included SCAP, MBTPS1, and MBTPS2, suggesting that the SREBP axis regulates additional mediators of LDL endocytosis beyond LDLR, consistent with clinical findings that statins reduce LDL cholesterol and mortality in LDLR null patients with homozygous familial hypercholesterolemia[31].